Patents by Inventor James Cardia

James Cardia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNA interference in ocular indications
    Patent number: 10184124
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: January 22, 2019
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia, Pamela A. Pavco
  • RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
    Publication number: 20180371464
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Application
    Filed: March 12, 2018
    Publication date: December 27, 2018
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
  • RNA INTERFERENCE IN SKIN INDICATIONS
    Publication number: 20180327748
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Application
    Filed: February 26, 2018
    Publication date: November 15, 2018
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
  • Reduced size self-delivering RNAi compounds
    Patent number: 10041073
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. The RNAi constructs may be, for instance, miRNA constructs that are miRNA modulators.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: August 7, 2018
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • NUCLEIC ACID MOLECULES TARGETING SUPEROXIDE DISMUTASE 1 (SOD1)
    Publication number: 20180195072
    Abstract: Aspects of the invention relate to methods for treating ALS comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule that is directed against a gene encoding superoxide dismutase 1 (SOD1).
    Type: Application
    Filed: July 6, 2016
    Publication date: July 12, 2018
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: James Cardia, Michael Byrne, Karen G. Bulock, Pamela A. Pavco, Lyn Libertine
  • RNA interference in dermal and fibrotic indications
    Patent number: 9963702
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: May 8, 2018
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
  • RNA interference in skin indications
    Patent number: 9938530
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: April 10, 2018
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
  • RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
    Publication number: 20170067056
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Application
    Filed: April 14, 2016
    Publication date: March 9, 2017
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
  • METHODS FOR TREATING CANCER USING NUCLEIC ACIDS TARGETING MDM2 OR MYCN
    Publication number: 20170051288
    Abstract: Aspects of the invention relate to methods for treating cancer by administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule that is directed against a gene encoding mouse double minute 1 homolog (MDM1), mouse double minute 2 homolog (MDM2), mouse double minute 3 homolog (MDM3), mouse double minute 4 homolog (MDM4) or V-myc myelocytomatosis viral related oncogene (MYCN) for treating cancer. Further aspects of the invention relate to nucleic acid molecules and compositions comprising nucleic acid molecules.
    Type: Application
    Filed: April 28, 2015
    Publication date: February 23, 2017
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Michael Byrne, Karen G. Bulock, James Cardia
  • RNA INTERFERENCE IN SKIN INDICATIONS
    Publication number: 20170009239
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Application
    Filed: February 11, 2016
    Publication date: January 12, 2017
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
  • METHODS FOR TREATMENT OF WOUND HEALING UTILIZING CHEMICALLY MODIFIED OLIGONUCLEOTIDES
    Publication number: 20160304875
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications. Aspects of the invention provide nucleic acid molecules for the prophylactic treatment of wounding to reduce scarring. Herein, it is demonstrated that a specific nucleic acid molecule, RXI-109 (targeting connective tissue growth factor (CTGF)), given prophylactically, reduces scarring during wound healing.
    Type: Application
    Filed: December 4, 2014
    Publication date: October 20, 2016
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Gerard Cauwenbergh, Pamela A. Pavco, Lyn Libertine, Karen G. Bulock, James Cardia
  • REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
    Publication number: 20160244765
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.
    Type: Application
    Filed: September 25, 2015
    Publication date: August 25, 2016
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • RNA interference in dermal and fibrotic indications
    Patent number: 9340786
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: May 17, 2016
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
  • REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
    Publication number: 20160130578
    Abstract: The present invention relates to methods for in vivo administration of sd-rxRNA molecules.
    Type: Application
    Filed: June 2, 2015
    Publication date: May 12, 2016
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • RNA INTERFERENCE IN OCULAR INDICATIONS
    Publication number: 20160115482
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Application
    Filed: June 2, 2015
    Publication date: April 28, 2016
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia, Pamela A. Pavco
  • RNA interference in skin indications
    Patent number: 9303259
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: April 5, 2016
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
  • Reduced size self-delivering RNAi compounds
    Patent number: 9175289
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: November 3, 2015
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • RNA interference in ocular indications
    Patent number: 9095504
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: August 4, 2015
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • Reduced size self-delivering RNAi compounds
    Patent number: 9080171
    Abstract: The present invention relates to methods for in vivo administration of sd-rxRNA molecules.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: July 14, 2015
    Assignee: RXi Parmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
    Publication number: 20140364482
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.
    Type: Application
    Filed: May 15, 2014
    Publication date: December 11, 2014
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia